pan-AKT kinase inhibitor GSK690693

Drug Overview

pan-AKT kinase inhibitor GSK690693 is an investigational, orally bioavailable, small-molecule inhibitor targeting all three isoforms of the AKT kinase: AKT1, AKT2, and AKT3. Chemically, it is an aminofurazan-derived compound that acts as a potent, ATP-competitive antagonist of the PI3K/AKT signaling pathway.

In the clinical landscape of March 2026, GSK690693 remains primarily a subject of academic and early-phase clinical interest rather than a widely approved therapeutic. The AKT (Protein Kinase B) family is a central “hub” for cell survival, metabolism, and growth. When this pathway is hyper-activated—due to mutations in PIK3CA, loss of PTEN, or amplification of the AKT genes—it drives uncontrolled tumor cell proliferation and resistance to apoptosis. GSK690693 was designed to “short-circuit” this hub by binding directly to the ATP-binding pocket of the AKT proteins. While it has shown robust activity in preclinical models of breast, ovarian, and prostate cancers, its clinical journey has been historically complicated by the specific metabolic side effects inherent to blocking AKT, particularly transient hyperglycemia (high blood sugar).

• Generic Name: pan-AKT kinase inhibitor GSK690693.
• Code Name: GSK690693.
• Drug Class: ATP-competitive pan-AKT Inhibitor.
• Mechanism: Competitive inhibition of AKT1, 2, and 3, preventing phosphorylation of downstream targets such as GSK3β, PRAS40, and FOXO transcription factors.
• Route of Administration: Intravenous (IV) or Oral (investigated in various schedules).
• FDA Approval Status: Investigational. As of March 2026, GSK690693 is not FDA-approved. Its primary Phase I clinical trials were completed several years ago, and current research focuses on specific pediatric applications and AI-driven combination screenings.

What Is It and How Does It Work? (Mechanism of Action)

GSK690693 works by “jamming” the energy intake of the AKT proteins, effectively silencing the growth signals they send to the cell.

1. ATP-Competitive Blockade

Most kinases require ATP (cellular energy) to function. GSK690693 is an ATP-competitive inhibitor, meaning it mimics the shape of ATP and sits in the kinase’s active site.

• The Targeted Strike: It inhibits AKT1 ( IC_{50} ≈ 2 nM), AKT2 ( IC_{50} ≈ 13 nM), and AKT3 ( IC_{50} ≈ 9 nM).
• The Cascade Failure: By blocking AKT, the drug prevents the phosphorylation (activation) of downstream proteins like GSK3β, PRAS40, and mTORC1.

2. Induction of Apoptosis

AKT is primarily a “survival” kinase. When it is active, it blocks “suicide” signals within the cell.

• FOXO Activation: Inhibition of AKT allows FOXO3A transcription factors to enter the nucleus, where they turn on genes that trigger apoptosis (programmed cell death).
• Sensitization: In many cancers, AKT is what allows the cell to survive chemotherapy. GSK690693 “re-sensitizes” the cell, making it more likely to die when exposed to stress.

3. Metabolic Consequences

Because AKT2 is a major player in how insulin works in the body, blocking it has immediate metabolic effects. The drug effectively prevents cells from taking up glucose, leading to a temporary “diabetic-like” state in the patient.

Clinical Indications and Research Status (2026)

Research in 2024–2026 has shifted toward identifying specific “niche” populations where GSK690693 may provide a unique benefit:

• Pediatric Solid Tumors: Investigated by the Pediatric Preclinical Testing Program (PPTP), where it showed significant activity in osteosarcoma and Ewing sarcoma models.
• Hematologic Malignancies: Preclinical data suggests high sensitivity in Acute Lymphoblastic Leukemia (ALL) and certain Non-Hodgkin Lymphomas.
• Kaposiform Lymphangiomatosis (KLA): A breakthrough study in 2025 used zebrafish models and AI-based screening to identify GSK690693 as a promising candidate for this rare vascular disease.
• Solid Tumors (Historical): Phase I trials (NCT00493818) previously evaluated the drug in patients with breast, ovarian, and prostate cancers. While it showed the ability to hit its target (pharmacodynamic effect), single-agent efficacy was often limited, leading to a focus on combination therapies.

Dosage and Administration Protocols

As an investigational agent, dosing for GSK690693 was historically explored to find the balance between target inhibition and metabolic safety.

Clinical Efficacy and Research Results (2024–2026)

Recent data have refined our understanding of how this drug can be most effectively used:

• Longevity Research (2021–2026): In a surprising turn, research in Drosophila models showed that GSK690693 could extend lifespan and improve oxidative resistance, though these findings are far from human anti-aging applications.
• Biomarker Sensitivity: Data confirms that tumors with PIK3CA mutations or PTEN loss are the most sensitive to GSK690693, providing a path for “biomarker-selected” clinical trials.
• Synergy with mTOR Inhibitors: 2025 screenings indicate that combining GSK690693 with mTOR inhibitors (like everolimus) can prevent the “feedback loops” that often allow AKT signaling to restart.

Safety Profile and Side Effects

The primary challenge with GSK690693 is its impact on the body’s global glucose metabolism.

1. Transient Hyperglycemia

Because AKT2 is essential for glucose transport, its inhibition leads to high blood sugar.

• Symptoms: Increased thirst, frequent urination, and fatigue.
• Observation: In animal models, blood glucose typically peaks 2–4 hours after dosing and returns to baseline within 10 hours.

2. Gastrointestinal Effects

• Symptoms: Nausea and diarrhea are common “off-target” effects seen in early-phase trials.

3. Hematologic Toxicity

• Neutropenia: A drop in white blood cell counts can occur, though it is usually less severe than with traditional chemotherapy.

Research Areas

In the fields of Stem Cell and Regenerative Medicine, GSK690693 is being used to study “Cellular Senescence.” Researchers are investigating how “locking” the AKT pathway can force cancer cells into a permanent sleep state without causing the DNA damage associated with radiation. In 2026, there is also intense focus on “AI-Driven Drug Repurposing,” where the molecular structure of GSK690693 is being used as a template to design newer AKT inhibitors that avoid the “glucose-blocking” effect on AKT2.

Patient Management and Practical Recommendations

Pre-treatment Requirements:

• Blood Glucose Profile: A baseline Hemoglobin A1c and fasting glucose test are mandatory.
• Molecular Profiling: Screening for AKT pathway mutations (PIK3CA, PTEN, AKT) to ensure treatment relevance.

“Do’s and Don’ts” List:

• DO monitor your blood sugar levels closely if you are part of an AKT-inhibitor clinical trial.
• DO maintain a consistent diet to avoid making the transient hyperglycemia more severe.
• DON’T ignore sudden “blurry vision” or “intense thirst,” which are signs of high blood sugar.
• DON’T take any over-the-counter supplements that claim to “boost metabolism” or “manage sugar” without consulting your study team, as these can interfere with the drug’s efficacy markers.

Legal Disclaimer

The information provided is for educational and informational purposes only and does not constitute medical advice. pan-AKT kinase inhibitor GSK690693 is an investigational agent and is not approved by the U.S. FDA for commercial use. Access is restricted exclusively to registered clinical trials. Always consult with a board-certified oncologist regarding your specific diagnosis and eligibility for PI3K/AKT-directed research.